The inside story of Ranbaxy, a generic drug maker that committed criminal fraud by fabricating data to win FDA approvals:
“Thakur knew the drugs weren’t good. They had high impurities, degraded easily, and would be useless at best in hot, humid conditions. They would be taken by the world’s poorest patients in sub-Saharan Africa, who had almost no medical infrastructure and no recourse for complaints. The injustice made him livid.
“Ranbaxy executives didn’t care, says Kathy Spreen, and made little effort to conceal it. In a conference call with a dozen company executives, one brushed aside her fears about the quality of the AIDS medicine Ranbaxy was supplying for Africa. ‘Who cares?’ he said, according to Spreen. ‘It’s just blacks dying.’”
Get the Longreads Weekly Email